Revvity Exceeds Q1 Expectations and Announces Strategic Divestiture of China Immunodiagnostics Business
Summary
Revvity reported strong Q1 2026 financial results, exceeding expectations, and announced the strategic divestiture of its China Immunodiagnostics business for up to $200 million, updating full-year guidance accordingly.
Key Events
-
Strong Q1 Financial Performance
Revvity reported Q1 2026 revenue of $711 million, a 7% year-over-year increase, with 3% organic growth (6% pro forma organic growth). Adjusted EPS from continuing operations reached $1.06, surpassing prior expectations.
-
Strategic Divestiture of China Immunodiagnostics Business
The company announced its intention to divest its Immunodiagnostics business in China (China IDX), which accounted for approximately 6% of its FY2025 revenue. A letter of intent has been signed for a sale of up to $200 million, with a potential consideration of $140 million reflected in pro forma statements, and is expected to close in 2027. This divestiture will result in a $55 million loss on probable disposition.
-
Updated Full-Year 2026 Guidance
Revvity updated its full-year 2026 guidance on a pro forma basis, forecasting total revenue of $2.81-$2.84 billion, pro forma organic revenue growth of 3%-4%, and pro forma adjusted EPS of $5.20-$5.30, reflecting the exclusion of the divested China IDX business.
Analysis
Revvity, Inc. reported strong first-quarter results, with revenue increasing 7% year-over-year to $711 million and adjusted EPS of $1.06, both exceeding expectations. Concurrently, the company announced a strategic decision to divest its Immunodiagnostics business in China (China IDX), which represented approximately 6% of its total fiscal year 2025 revenue. The sale is for up to $200 million, with a potential consideration of $140 million reflected in pro forma statements, and is expected to close in 2027. This divestiture, while resulting in a $55 million loss on probable disposition, is framed as a portfolio optimization. The company has updated its full-year 2026 guidance on a pro forma basis, reflecting the exclusion of the divested business. This filing provides comprehensive details following earlier news reports of strong Q1 performance, and the strategic divestiture marks a significant shift in the company's operational focus, potentially streamlining its business and improving long-term profitability, especially as the stock trades near its 52-week low.
At the time of this filing, RVTY was trading at $85.18 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $9.7B. The 52-week trading range was $81.22 to $118.30. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.